Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III ‘Stop and Go' Study Results - A Turkish Oncology Group Trial

Publisher： Karger

E-ISSN： 1423-0232|85|6|328-335

ISSN： 0030-2414

Source： Oncology, Vol.85, Iss.6, 2013-11, pp. : 328-335

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

By  

Oncology, Vol. 83, Iss. 3, 2012-08 ,pp. : 151-157

Karger

Access to resources Recommend Favorite

Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 61-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)

By  

CANCER, Vol. 124, Iss. 4, 2018-02 ,pp. : 688-697

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

FOLFOX-4 Stop and Go and Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 70, Iss. 5, 2007-01 ,pp. : 345-350

Karger

Access to resources Recommend Favorite